Levetiracetam Injection
Product Images NDC 66298-0427

This is a comparison of adverse reactions reported for Levetiracetam and Placebo in a study with a total of 769 and 439 participants, respectively. The table shows the percentages and the number of occurrences of various adverse reactions for both groups. Adverse reactions such as asthenia, somnolence, headache, infection, dizziness, pain, pharyngitis, depression, nervousness, and others are listed. This information provides insights into the potential side effects associated with Levetiracetam compared to Placebo.*

This text shows a graph displaying the percentages of patients for placebo and two different doses of Levetiracetam (1,000 mg/day and 2,000 mg/day). It mentions that the results were statistically significant versus placebo.*

This text shows the percentage breakdown of patients in a study comparing Levetiracetam at 3,000 mg/day with a placebo. The data includes different percentages of patients under each category and specifies that the results were statistically significant compared to the placebo group. A total of 104 patients were in the placebo group, and 180 patients were part of the Levetiracetam group.*

This text appears to show results from a study comparing the effectiveness of placebo and Levetiracetam for a certain condition. The data includes percentages of patients for each treatment group and mentions that Levetiracetam showed statistical significance versus placebo. The sample sizes for each group are also provided (84 for placebo and 79 for Levetiracetam).*

This is a label for Levetiracetam, a medication used for intravenous infusion. It is contained in 24 single-dose bags, each containing 500 mg in 100 mL sodium chloride solution. The bags should be stored at room temperature between 20°C to 25°C. Before use, check for leaks by squeezing the bag. Discard if leaks are found. The expiration date and lot number are provided on the label. The medication is manufactured in Lake Zurich, IL, USA.*

The text provides information about Levetiracetam 100 mL in 0.82% Sodium Chloride Injection. Each 100 mL contains Levetiracetam 500 mg, Sodium Chloride 820 mg, Glacial Acetic Acid 5.5 mg, and buffered at approximately pH 5.5. It is recommended to use immediately once removed from overwrap and infuse over a period of 15 minutes. The product should not be diluted before use and should only be used if the solution is clear. The usual adult dosage can be found in the package insert. The solution is stored at 20° to 25°C (68° to 77°F). The container is a single-dose dual port bag. The container closure is not made with natural rubber latex and is both Non-PVC and Non-DEHP. Manufactured for: Fresenius Kabi.*

This is a Levetiracetam solution in 0.82% Sodium Chloride Injection with a concentration of 500 mg in 100 mL (5 mg per mL). It is intended for intravenous infusion use only and is a prescription medication. The code numbers shown are 403112A and 01-79-12-001.*

This text shows the percentage data related to the efficacy of Levetiracetam at different dosages (1,000 mg/day and 3,000 mg/day) compared to a placebo. The percentages represent the response rates among patients. The text indicates that the response rates for both dosages of Levetiracetam are statistically significant when compared to the placebo group.*